[PDF] Top 20 The influence of vitreomacular adhesion on outcomes after aflibercept therapy for neovascular age-related macular degeneration.

... Conclusions: Visual acuity, retinal thickness and age at the baseline examination, but not PVD status, are associated with functional and anatomical outcomes following intra-vitreal af[r] ... See full document

... mean age of the patient was 80 years (range, 58–89 years), and the series included ten men and seven ...to aflibercept. In the 12 months prior to switching to aflibercept, no eyes included in the ... See full document

... The prevalence of ORT continuously increased during the follow-up period, in both groups. In the ranibizumab group its prevalence almost quadrupled at the 24-month follow-up, while there was a doubling in the ... See full document

... The large variability of factors influencing the healing process may explain why the variables assessed independ- ently in our study did not provide a significant amount of information to the model. Since societal ... See full document

... functioning following anti-VEGF treatment switch, this study was conducted to determine and evaluate change from base- line to week 12 in Pelli–Robson CS as the primary clinical end point in patients with recalcitrant ... See full document

... and Aflibercept are both licensed for treat- ment of nAMD [5, ...whereas Aflibercept is a recombinant fusion protein of components of VEGF receptor and antagonizes VEGF-A, VEGF-B and placental growth factor ... See full document

... anatomical outcomes and sensitivity analyses were determined using data from 502 patients (FAS) and visual acuity outcomes were analysed from 353 patients with visual acuity data at baseline and month 12 ... See full document

... with macular edema, such as: neovascular age- related macular degeneration (nAMD); Irvine–Gass syndrome (IGS); vasoproliferative retinal tumors (VPRTs); retinal telangiectasia ... See full document

... deviation) age of the 50 patients was 81 ± 17 ...real-world outcomes of ranibizumab therapy in this initial cohort of patients with nAMD are comparable with those reported in the pivotal, randomized, ... See full document

... that macular dryness ranged from dry to slightly ...acuity. After correcting for time from initial examination, thereby eliminating the effects of atrophy of the outer layer of the retina due to a long ... See full document

... of GA at the inner/outer segment junction of 30 patients with AMD. Interestingly, they found outer retinal disruption that extended beyond the borders of GA, which are visualized as focal hyporeflective areas on en-face ... See full document

... of neovascular macular degenera- tion, a disease that can be blinding and is epidemic in the developing world ...vascular macular degeneration suggest benefits similar to those of ranibizumab ... See full document

... While improved visual results were welcomed, the short-acting duration of anti-VEGF agents has demanded very frequent intravitreal injections and assessments in order to prevent vision loss. 2,4,5 The burden of care is ... See full document

... three aflibercept injections, then monitored for response, and found to have worsening persistent or recurrent ...response after repetitive administration of a pharmacological active substance, has been ... See full document

... Double-Masked, Sham Injection-Controlled Study of the Effi cacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovasularization with or without Classic CNV Secondary to Age-Related ... See full document

... Records of all anti-VEGF injections given from January 2011 to December 2014 were retrieved from the theatre register of Lagos (Ikeja and Victoria Island), Abuja and Ijebu centres of Eye Foundation Hospitals in Nigeria. ... See full document

... Subjects and methods: Of 88 Japanese AMD patients (28 men and 60 women, mean age: 72.7±7.5 years) who underwent intravitreal injection of ranibizumab for 3 years from 2010 to 2013, this study involved 12 eyes of ... See full document

... starting aflibercept, 13 patients had subretinal fluid (SRF), five had intraretinal fluid (IRF), four had PED, and baseline visual acuity (VA) was 62 approximate ETDRS ...weeks after Visit 3, VA had ... See full document

... patient age, duration between fi rst symptoms and treatment initiation, lesion size, absence or presence of intraretinal fl uid after end of the loading phase and after 12 months, and the number of ... See full document

... that Aflibercept has a binding affinity to various types of VEGF and also to Placental Growth Factor resulting in higher efficiency [3, ...of Aflibercept over Ranibizumab in clinical efficacy have been pro- ... See full document